Daewoong Pharmaceutical's Gastroesophageal Reflux Disease Treatment 'Pexuprazan' Receives Domestic Product Approval
[Asia Economy Reporter Gong Byung-sun] Daewoong Pharmaceutical announced on the 30th that its gastroesophageal reflux disease treatment 'Pexuprazan' has received marketing authorization approval from the Ministry of Food and Drug Safety in Korea.
Hot Picks Today
Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Will Soaring Semiconductor Prices Support a Gradual Stabilization of the Household Debt Ratio? Why [BOK Focus]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This treatment rapidly and reversibly inhibits H+·K+ ATPase compared to PPIs, suppressing acid secretion to provide fast and sustained effects. Additionally, it immediately improves heartburn symptoms regardless of day or night.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
